Related Experiment Videos
Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel
Asa Karlsson1, Sylvie Giuriato, Flora Tang
1Division of Oncology, Department of Medicine, Stanford University, CA 94305, USA.
Abstract:
The targeted inactivation of oncogenes may be a specific and effective treatment for cancer. However, because human cancers are the consequence of multiple genetic changes, the inactivation of one oncogene may not be sufficient to cause sustained tumor regression. Moreover, cancers are genomically unstable and may readily compensate for the inactivation of a single oncogene. Here we confirm by spectral karyotypic analysis that MYC-induced hematopoietic tumors are highly genetically complex and genomically unstable. Nevertheless, the inactivation of MYC alone was found to be sufficient to induce sustained tumor regression. After prolonged MYC inactivation, some tumors exhibited a distinct propensity to relapse. When tumors relapsed, they no longer required the overexpression of MYC but instead acquired novel chromosomal translocations. We conclude that even highly genetically complex cancers are reversible on the inactivation of MYC, unless they acquire novel genetic alterations that can sustain a neoplastic phenotype.
Insights
Targeting the MYC oncogene can reverse even complex cancers. However, tumors may relapse by acquiring new genetic changes, highlighting the need for comprehensive cancer therapies.
Area of Science:
- Oncology
- Cancer Genetics
- Molecular Biology
Background:
- Targeted oncogene inactivation is a promising cancer treatment strategy.
- Human cancers often involve multiple genetic alterations, complicating single-target therapies.
- Cancer genomic instability can lead to compensatory mechanisms and treatment resistance.
Purpose of the Study:
- To investigate the efficacy of MYC inactivation in genetically complex, MYC-induced hematopoietic tumors.
- To determine if MYC inactivation alone can induce sustained tumor regression.
- To explore the mechanisms of tumor relapse following MYC inactivation.
Main Methods:
- Spectral karyotyping to analyze tumor genetic complexity and instability.
- MYC inactivation as a therapeutic intervention.
- Monitoring tumor regression and relapse dynamics.
Main Results:
- MYC-induced hematopoietic tumors were confirmed to be genetically complex and unstable.
- Inactivation of MYC alone was sufficient to induce sustained tumor regression.
- Relapsed tumors no longer depended on MYC overexpression but had acquired new chromosomal translocations.
Conclusions:
- MYC inactivation can reverse even highly complex cancers.
- Tumor relapse can occur through the acquisition of novel genetic alterations that sustain the neoplastic phenotype.
- Targeting MYC is a viable strategy, but resistance mechanisms must be considered for durable responses.